Trividia Health Announces Jonathan Chapman as President and Chief Executive Officer
15.9.2021 11:00:00 EEST | Business Wire | Press release
Trividia Health, Inc., a leading supplier of blood glucose monitoring systems, announced today that Jonathan Chapman has been appointed as President and Chief Executive Officer. Mr. Chapman succeeds Scott Verner in the role.
Mr. Chapman brings over 20 years of leadership experience in the medical device industry, with an accomplished track record of driving growth, developing strategic alliances, launching products globally, and optimizing business operations.
In addition to his newly assumed responsibilities at Trividia Health, Mr. Chapman will continue to serve as President and Chief Executive Officer of PTS Diagnostics, Inc.
“Jonathan has proven himself as the right leader for PTS Diagnostics and is the right leader for Trividia,” said Shaobo Li, Chairman of the Board at both Trividia Health and PTS Diagnostics. “Jonathan’s extensive background in successfully running medical device companies and his business development skills will help both organizations to reach the next level of growth and evolution. Jonathan is a results-oriented, dynamic, and innovative business leader. I am confident he has the right track record, commitment, vision and judgment to lead Trividia and PTS Diagnostics.”
“I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes,” said Jonathan Chapman, President and CEO of Trividia Health and PTS Diagnostics. “I look forward to working with my colleagues at Trividia. With their support, focus on customers and continuing dedication, we will build on Trividia’s legacy of bringing leading innovation to patients across the globe.”
Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. Trividia is confident that his international experience will be immensely valuable when leading the organization across global markets.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company with over 30 years experience in the industry. Based in Fort Lauderdale, Florida, Trividia is a leading developer, manufacturer and marketer of advanced performance products for people and pets with diabetes. With products sold under the TRUE brand, store brand labels and Healthy Tracks for Pets, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005226/en/
Contact information
Neal Bhattacharya, Sr. Director, Product Marketing
(800) 342-7226, ext. 3150 – nbhattacharya@trividiahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 20:00:00 EEST | Press release
Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1 In addition to the broad injunction against Siemens, recall and destruction of infringing systems, Hologic will rec
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 19:30:00 EEST | Press release
RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, date, and availability, streamlining ancillary revenue management for properties of any size. Courte
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 18:42:00 EEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program16.6.2026 18:00:00 EEST | Press release
IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/ The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016. “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a global perspective,” says Valery Claude, program sponsor and senio
Fenchurch Advisory Partners to Combine With Broadhaven Capital Partners, Creating the Preeminent International Investment Bank Serving the Financial Services Sector16.6.2026 17:30:00 EEST | Press release
Fenchurch Advisory Partners has entered into a definitive agreement to combine with Broadhaven Capital Partners, a leading independent advisory firm to the financial technology and financial services sectors in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616214669/en/ Fenchurch is one of the most respected investment banking advisory firms dedicated exclusively to the financial services sector. With offices in London, New York and Paris, Fenchurch provides trusted, independent advice to corporates and financial sponsors across insurance, asset and wealth management, banking, and specialty finance. In 2025, Fenchurch advised on 27 transactions, ranking as the number one adviser to the financial services sector in the UK and Europe. Founded in 2009, Broadhaven has established itself as a premier investment bank advising corporates and financial sponsors on M&A, capital raising, and strategic transactions,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom